[go: up one dir, main page]

CU20130057A7 - Polipéptidos del factor ix modificados y usos de los mismos - Google Patents

Polipéptidos del factor ix modificados y usos de los mismos

Info

Publication number
CU20130057A7
CU20130057A7 CU2013000057A CU20130057A CU20130057A7 CU 20130057 A7 CU20130057 A7 CU 20130057A7 CU 2013000057 A CU2013000057 A CU 2013000057A CU 20130057 A CU20130057 A CU 20130057A CU 20130057 A7 CU20130057 A7 CU 20130057A7
Authority
CU
Cuba
Prior art keywords
polipeptides
same
modified factor
factor
modified
Prior art date
Application number
CU2013000057A
Other languages
English (en)
Inventor
Alan Brooks
Chandra Patel
Xiaoqiao Jiang
Uwe Gritzan
Heiner Apeler
Jun Wang
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43529743&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20130057(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of CU20130057A7 publication Critical patent/CU20130057A7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La invención se refiere a procedimientos para producir polipéptidos del Factor IX modificados.
CU2013000057A 2009-07-31 2013-04-19 Polipéptidos del factor ix modificados y usos de los mismos CU20130057A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23055109P 2009-07-31 2009-07-31
PCT/US2010/044177 WO2011014890A1 (en) 2009-07-31 2010-08-02 Modified factor ix polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
CU20130057A7 true CU20130057A7 (es) 2013-06-28

Family

ID=43529743

Family Applications (3)

Application Number Title Priority Date Filing Date
CU20120018A CU20120018A7 (es) 2009-07-31 2012-01-30 Polipéptidos del factor ix modificados y usos de los mismos
CU2013000057A CU20130057A7 (es) 2009-07-31 2013-04-19 Polipéptidos del factor ix modificados y usos de los mismos
CU2013000058A CU20130058A7 (es) 2009-07-31 2013-04-19 Polipéptidos del factor ix modificados y usos de los mismos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CU20120018A CU20120018A7 (es) 2009-07-31 2012-01-30 Polipéptidos del factor ix modificados y usos de los mismos

Family Applications After (1)

Application Number Title Priority Date Filing Date
CU2013000058A CU20130058A7 (es) 2009-07-31 2013-04-19 Polipéptidos del factor ix modificados y usos de los mismos

Country Status (21)

Country Link
US (1) US20120164130A1 (es)
EP (1) EP2461821A4 (es)
JP (1) JP2013500726A (es)
KR (1) KR20120060209A (es)
CN (1) CN102573890A (es)
AU (1) AU2010278721A1 (es)
BR (1) BR112012002072A2 (es)
CA (1) CA2769258A1 (es)
CL (1) CL2012000238A1 (es)
CR (1) CR20120052A (es)
CU (3) CU20120018A7 (es)
DO (1) DOP2012000030A (es)
EA (1) EA201290069A1 (es)
EC (1) ECSP12011637A (es)
GT (1) GT201200023A (es)
IN (1) IN2012DN00908A (es)
MX (1) MX2012001346A (es)
PE (1) PE20121643A1 (es)
SG (1) SG178119A1 (es)
WO (1) WO2011014890A1 (es)
ZA (1) ZA201200716B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007333049B2 (en) 2006-12-15 2014-02-20 Takeda Pharmaceutical Company Limited Factor VIIa-(poly)sialic acid conjugate having prolonged in vivo half-life
DK3581650T3 (da) 2008-09-15 2023-03-13 Uniqure Biopharma B V Faktor ix polypeptidmutant, anvendelse deraf og en fremgangsmåde til fremstilling deraf
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
KR101832937B1 (ko) 2009-07-27 2018-02-28 박스알타 인코퍼레이티드 혈액 응고 단백질 복합체
HUE028056T2 (en) 2009-07-27 2016-11-28 Baxalta GmbH Blood coagulation protein conjugates
US9795683B2 (en) 2009-07-27 2017-10-24 Lipoxen Technologies Limited Glycopolysialylation of non-blood coagulation proteins
KR101969601B1 (ko) * 2010-07-30 2019-04-17 박스알타 인코퍼레이티드 옥심 결합용 친핵성 촉매
HUE049352T2 (hu) 2010-12-22 2020-09-28 Baxalta GmbH Anyagok és módszerek egy vízoldható zsírsavszármazéknak egy fehérjéhez való konjugálására
DK2794665T3 (da) * 2011-12-19 2018-01-29 Dilafor Ab Ikke-antikoagulative glycosaminoglycaner omfattende disaccharid-gentagelsesenhed og medicinsk anvendelse deraf
BR112015011462A2 (pt) * 2012-11-20 2017-09-26 Univ North Carolina Chapel Hill processos e composições para proteínas fator ix modificadas
US10105447B2 (en) * 2013-03-13 2018-10-23 Elanco Us Inc. Method of treating obesity in a companion animal comprising administering a modified canine leptin polypeptide
TW201519900A (zh) * 2013-04-28 2015-06-01 Bayer Healthcare Llc 用於誘導對凝血因子蛋白之免疫耐受性的組成物及方法
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
BR112018002150A2 (pt) 2015-08-03 2018-09-18 Bioverativ Therapeutics Inc proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas
JP7181855B2 (ja) * 2016-07-27 2022-12-01 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア 第ｉｘ因子の機能を調節するための組成物及び方法
GB201813528D0 (en) 2018-08-20 2018-10-03 Ucl Business Plc Factor IX encoding nucleotides
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
AU2019360270B2 (en) 2018-10-18 2025-08-07 Intellia Therapeutics, Inc. Compositions and methods for expressing factor IX.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002254731A1 (en) * 2001-04-25 2002-11-05 The Regents Of The University Of California Method to treat hemophilia by hepatic gene transfer of factor viii/ix with vesicle vector
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
WO2005055950A2 (en) * 2003-12-03 2005-06-23 Neose Technologies, Inc. Glycopegylated factor ix
US8383388B2 (en) * 2006-06-19 2013-02-26 Catalyst Biosciences, Inc. Modified coagulation factor IX polypeptides and use thereof for treatment
US7700734B2 (en) * 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof

Also Published As

Publication number Publication date
AU2010278721A1 (en) 2012-02-16
KR20120060209A (ko) 2012-06-11
BR112012002072A2 (pt) 2016-11-08
SG178119A1 (en) 2012-03-29
CR20120052A (es) 2012-06-04
ZA201200716B (en) 2013-07-31
WO2011014890A1 (en) 2011-02-03
EA201290069A1 (ru) 2012-07-30
MX2012001346A (es) 2012-02-17
IN2012DN00908A (es) 2015-04-03
CU20120018A7 (es) 2012-06-21
ECSP12011637A (es) 2012-02-29
DOP2012000030A (es) 2012-02-29
CU20130058A7 (es) 2013-06-28
PE20121643A1 (es) 2012-11-25
CN102573890A (zh) 2012-07-11
CA2769258A1 (en) 2011-02-03
EP2461821A4 (en) 2013-07-03
US20120164130A1 (en) 2012-06-28
GT201200023A (es) 2014-01-27
EP2461821A1 (en) 2012-06-13
JP2013500726A (ja) 2013-01-10
CL2012000238A1 (es) 2012-10-05

Similar Documents

Publication Publication Date Title
CU20130057A7 (es) Polipéptidos del factor ix modificados y usos de los mismos
GT201400147A (es) Pirimidinas y triazinas fusionadas sustituidas y su uso
CR20140512A (es) Dispositivos y metodos para la fabricación de aditivos de componentes de implante
PA8836801A1 (es) Polipeptidos g-csf de bovino modificados y sus usos
ECSP14005975A (es) Anticuerpos anti-PHF-tau y sus usos
MX2019002513A (es) Composiciones de sustitutos de carne.
UY34538A (es) Heteroarilos y usos de los mismos
HN2010000084A (es) Derivados de sulfonamida
UY34472A (es) Derivados modificados de 4-fenil-piridina
NI201300080A (es) Formas sólidas de 3 - ( 5 - amino - 2 - metil - 4 - oxo - 4h - quinazolin - 3 - il ) - piperidin - 2, 6 - diona, y sus composiciones farmacéuticas y usos
CL2012000590A1 (es) Proceso para preparar w-transaminasa (r)-selectiva.
AP2015008737A0 (en) Interleukin-2 muteins for the expansion of t-regulatory cells
BR112013028512A2 (pt) cápsula
PL2324831T3 (pl) Terapia pirfenidonem z wykluczeniem fluwoksaminy
UY34271A (es) Anticuerpos anti-tie2 y usos de los mismos
UY34467A (es) Procedimiento para la preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
CL2009001624S1 (es) Maquina para preparar bebidas.
BR112015012907A2 (pt) composição de cuidado pessoal
MX2016004556A (es) Composicion de hueso comprimido y metodo para usar la misma.
CO7020877A2 (es) Anticuerpos anti-asic1 y usos de los mismos
UY34167A (es) Pirrolotriazinas sustituidas con hidroximetilarilo y sus usos
BR112013005855A2 (pt) heteroarilas fundidas e seus usos
UY34018A (es) Derivados glucósidos y usos de los mismos
DK2533895T3 (da) Fremgangsmåde til fremstilling af hydrogeneret biodiesel
GT201000031S (es) Diseño de confitería